Neurocrine Biosciences Inc (NBIX)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 55.72% | 55.96% | 54.64% | 53.07% | 50.66% | 49.87% | 47.92% | 45.95% | 45.00% | 43.99% | 42.26% | 44.61% | 47.34% | 58.39% | 61.08% | 66.15% | 67.49% | 67.37% | 69.30% | 66.99% |
| Operating profit margin | 24.22% | 25.82% | 25.33% | 23.48% | 13.33% | 11.47% | 9.03% | 8.65% | 17.64% | 8.37% | 5.46% | 6.25% | 9.25% | 20.05% | 12.05% | 13.27% | 15.97% | 13.77% | 27.97% | 26.92% |
| Pretax margin | 20.63% | 23.27% | 21.11% | 23.75% | 17.64% | 14.15% | 14.03% | 5.86% | 15.15% | 6.29% | 1.22% | 8.06% | 9.15% | 14.94% | 6.86% | 9.29% | 10.45% | 10.19% | 22.33% | 21.79% |
| Net profit margin | 14.49% | 17.22% | 16.02% | 18.69% | 13.26% | 10.73% | 10.57% | 4.20% | 10.95% | 4.46% | 1.01% | 6.02% | 8.09% | 42.35% | 36.08% | 39.33% | 39.90% | 9.18% | 20.88% | 20.46% |
Neurocrine Biosciences Inc's profitability ratios exhibit fluctuations over the analyzed periods.
1. Gross Profit Margin: The company's gross profit margin has been relatively high, indicating efficient cost management and strong pricing strategies. The margin declined from around 70% in mid-2020 to approximately 42% by mid-2022 before gradually increasing to 56% by the end of 2024.
2. Operating Profit Margin: Neurocrine Biosciences Inc's operating profit margin fluctuated significantly over the periods. It peaked at around 27% in mid-2020, dropped to about 5% in mid-2022, and recovered to approximately 25% by the end of 2024. This suggests varying levels of operational efficiency and profitability.
3. Pretax Margin: The pretax margin reflects the company's ability to control expenses and generate earnings before taxes. There were fluctuations in this margin as well, ranging from 1% in mid-2022 to 23% in early 2024. This indicates changes in the company's ability to generate profits before tax expenses.
4. Net Profit Margin: Neurocrine Biosciences Inc's net profit margin depicts the portion of revenue that translates into net income. The ratio varied from around 1% in mid-2022 to approximately 19% in early 2024. This highlights the company's profitability challenges and improvements over the analyzed periods.
Overall, while the company experienced fluctuations in its profitability margins, it managed to demonstrate resilience and recovery in its operations and earnings generation by the end of the analysis period.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 15.34% | 16.37% | 16.22% | 13.37% | 7.72% | 7.16% | 5.76% | 5.58% | 10.51% | 5.10% | 3.29% | 3.46% | 4.95% | 10.44% | 6.23% | 7.34% | 9.40% | 9.32% | 18.11% | 17.05% |
| Return on assets (ROA) | 9.18% | 10.92% | 10.26% | 10.65% | 7.68% | 6.71% | 6.75% | 2.71% | 6.52% | 2.72% | 0.61% | 3.33% | 4.32% | 22.05% | 18.64% | 21.77% | 23.48% | 6.22% | 13.51% | 12.96% |
| Return on total capital | 19.57% | 20.75% | 19.81% | 19.89% | 15.09% | 12.81% | 12.89% | 5.11% | 12.94% | 6.14% | 2.06% | 6.65% | 7.44% | 10.97% | 6.12% | 8.25% | 9.66% | 11.13% | 20.13% | 19.77% |
| Return on equity (ROE) | 13.18% | 14.19% | 13.52% | 15.49% | 11.19% | 9.54% | 9.52% | 3.80% | 9.05% | 3.77% | 0.86% | 5.13% | 6.52% | 33.05% | 28.51% | 33.34% | 36.17% | 11.61% | 24.64% | 25.20% |
Neurocrine Biosciences Inc's profitability ratios show fluctuating trends over the periods analyzed.
- Operating return on assets (Operating ROA) declined from 17.05% in March 2020 to 3.29% in June 2022, before gradually improving to 16.37% in September 2024. The latest figure indicates a strong operating performance relative to the company's assets.
- Return on assets (ROA) fluctuated between 0.61% in June 2022 and 23.48% in December 2020. Despite this variation, the ratio improved to 10.92% by September 2024, suggesting efficient asset utilization.
- Return on total capital ranged from 2.06% in June 2022 to 20.75% in September 2024. This metric highlights the return generated from all forms of capital employed in the business.
- Return on equity (ROE) varied widely, from 0.86% in June 2022 to 36.17% in December 2020. The ratio declined over time but showed signs of recovery, reaching 14.19% by September 2024. ROE signifies the return earned on shareholders' equity investments.
Overall, Neurocrine Biosciences Inc's profitability ratios demonstrate fluctuations in performance, with periods of both decline and improvement. Investors may consider these trends when evaluating the company's financial health and future prospects.